Severe Sepsis Clinical Trial
Official title:
Single-blind Randomized Trial of a Commercially Sold Electronic Health Record Based Severe Sepsis Early Warning Best Practice Alert.
The investigators hypothesize that implementing an electronic health record-based early warning system for severe infections (severe sepsis) will decrease the time to antibiotic order. The study will consist of an algorithm which will monitor lab values, vital signs, and nursing documentation for signs of severe sepsis. When these criteria are met, an alert will be delivered via the electronic health record to a nurse and doctor and simultaneously an alert via pager to another nurse. The investigators plan to randomize which patients will generate these alerts and analyze the data after collecting information for approximately 6 months which will be sufficient to detect a 10% difference in the two patient groups.
Sepsis is the leading cause of mortality at Stanford Hospital and ranks only 54th out of 119
hospitals according to UHC data with approximately 60 episodes of documented sepsis per
quarter. Based on some preliminary data, there is concern that sepsis is both being
recognized late and not treated in a timely enough fashion. In fact, there are evidence and
expert guidelines that suggestion-delaying antibiotics in a patient with septic shock can
increase mortality by 6.7% per hour (1C recommendation in severe sepsis by the Surviving
Sepsis Campaign authors). As part of a hospital wide initiative to improve our treatment of
sepsis and ultimately reduce sepsis-related mortality, an EHR-based clinical decision
support (aka BPA) will be implemented. This BPA will be an algorithm that will alert
practitioners and trigger clinical workflow after criteria are met. Criteria include lab
values, vital signs and nursing flow sheet descriptions of perfusion (Table 1). The
algorithm will alert when, in a 24 hour period, three criteria from the manifestation group,
one criteria from the suspected infection group and one criteria from the organ dysfunction
group. Note that one variable (eg creatinine > 2) can fulfill criteria in more than one
group. Figure 1 contains details of proposed EHR workflow. After criteria are met, whomever
is next in the chart with RN or MD user-type, will receive an interruptive alert via the
EHR; simultaneously a page will automatically be sent by the EHR to a crisis nurse who will
assess the patient and notify the primary MD and RN.
Electronic early warning systems and predictive analytic tools lack rigorous evaluation and
standardization. There are literature demonstrating unintended consequences and even harms
from the implementation of electronic health records and clinical decision support tools. As
such, this is a situation of clinical equipoise in which it is unclear whether this quality
improvement initiative will benefit patient care or not. To evaluate this question, the
severe sepsis BPA will be initiated in a randomized fashion with each patient randomly
assigned to either potentially generate this alert as described above or to generate this
alert silently such that only quality improvement staff will be aware that criteria have
been met via the EHR.
This is a randomized, single-blind prospective quality improvement study. Patients will be
randomized by encounter to have the BPA visible or invisible during hospital admission. If
visible, the alert will display to the primary nurse and physician and send a page to a
crisis nurse when BPA criteria are met. If invisible, the alert will be triggered but will
be invisible to the care team (only visible to quality improvement staff via the EHR)
- Inclusion criteria
o Admitted to Stanford Hospital (inpatient or observation status) to any medical or
surgical service for at least 24 hours during the period of the study
- Exclusion criteria
o Admitted to an intensive-care level service (MICU, SICU, CVICU, CCU)
- While ideally we will make this available to ICU patients, the alert is likely to be
far less specific in ICU patients and less clinically useful given the high level of
care (eg 1:1 nursing and hourly vital signs).
o Patient code status is DNR/C (comfort care only)
- These patients would not be appropriate to treat with antibiotics and aggressive care
generally give the comfort care goals of care.
o Emergency Department patients (may be included in the near future)
- Primary endpoints
o Percentage of patients receiving antibiotics within three hours
- Secondary endpoints
- Percentage of patients with hypotension or lactate >= 4 who received at least 30
ml/kg fluid
- Rate of 3 hour sepsis bundle completion (serum lactate, blood cultures,
antibiotics)
- Length of hospital stay
- Cost of hospital stay per day and overall cost
- Mortality at hospital discharge
- Sample size and duration
- Based on prior studies, we predict a 10-15% difference in one or more primary
endpoints (see Sawyer et. Al, Crit Care Med. 2011 March, 39:469)
- We therefore anticipate enrolling 1500 patients, an estimated 150 of whom will
have true sepsis, over approximately six months, to achieve 80% power.
- Analysis will compare endpoints among all patients in the treatment and control groups
- Early stopping will be decided by an oversight committee which will review data at 3
months. If there is statistically significant different of more than 10% between
groups, the study will be terminated early and in discussion with hospital quality and
safety committee, use whichever strategy is superior for all patients in the hospital.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Completed |
NCT02539147 -
Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis
|
N/A | |
Completed |
NCT01929772 -
German Lactat Clearance in Severe Sepsis
|
N/A | |
Completed |
NCT01932814 -
Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?
|
N/A | |
Completed |
NCT01449721 -
Preemptive Resuscitation for Eradication of Septic Shock
|
N/A | |
Active, not recruiting |
NCT01162109 -
Zinc Therapy in Critical Illness
|
Phase 1 | |
Not yet recruiting |
NCT01211899 -
4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock
|
N/A | |
Completed |
NCT00934011 -
Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections
|
N/A | |
Recruiting |
NCT00335907 -
Protocol-driven Hemodynamic Support for Patients With Septic Shock
|
N/A | |
Completed |
NCT00463645 -
Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients
|
N/A | |
Completed |
NCT02361528 -
GM-CSF to Decrease ICU Acquired Infections
|
Phase 3 | |
Completed |
NCT02734550 -
(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis
|
N/A | |
Completed |
NCT02973243 -
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
|
N/A | |
Terminated |
NCT03895853 -
Early Metabolic Resuscitation for Septic Shock
|
Phase 2 | |
Completed |
NCT01945983 -
Early Use of Norepinephrine in Septic Shock Resuscitation
|
N/A | |
Completed |
NCT01598831 -
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
|
Phase 3 | |
Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A |